Center for Regenerative Medicine (CReM) of Boston University and Boston Medical Center
The Center for Regenerative Medicine (CReM) is a collaborative initiative between Boston University and Boston Medical Center focused on advancing stem cell research, regenerative medicine, and disease modeling, with a major emphasis on induced pluripotent stem cells (iPSCs). The center promotes open-source biology, sharing protocols, reagents, and data to accelerate scientific discovery and therapeutic development. CReM's mission is to heal the world through innovative research, education, and community outreach in regenerative medicine.
Industries
Nr. of Employees
small (1-50)
Center for Regenerative Medicine (CReM) of Boston University and Boston Medical Center
Products
Catalogued iPSC line biorepository
A searchable catalog of frozen iPSC lines including disease-specific, gene-edited and reporter lines available to researchers with associated characterization data and managed ordering.
PiSZ2
Alpha-1 Antitrypsin Deficiency human induced pluripotent stem cell line with genotype PiSZ.
PiSZ1
Alpha-1 Antitrypsin Deficiency human induced pluripotent stem cell line with genotype PiSZ.
CJD2CR
Creutzfeldt Jakob Disease E200K Carrier, CRISPR corrected human iPSC line derived from PBMCs using Sendai Virus reprogramming.
CJD13CR
Creutzfeldt Jakob Disease E200K Carrier, CRISPR corrected human iPSC line derived from PBMCs using Sendai Virus reprogramming.
BU3 NGST
Human iPSC-derived lung alveolar epithelial type 2 cells carrying an NKX2-1GFP reporter and an SFTPCtdTomato reporter.
Catalogued iPSC line biorepository
A searchable catalog of frozen iPSC lines including disease-specific, gene-edited and reporter lines available to researchers with associated characterization data and managed ordering.
PiSZ2
Alpha-1 Antitrypsin Deficiency human induced pluripotent stem cell line with genotype PiSZ.
PiSZ1
Alpha-1 Antitrypsin Deficiency human induced pluripotent stem cell line with genotype PiSZ.
CJD2CR
Creutzfeldt Jakob Disease E200K Carrier, CRISPR corrected human iPSC line derived from PBMCs using Sendai Virus reprogramming.
CJD13CR
Creutzfeldt Jakob Disease E200K Carrier, CRISPR corrected human iPSC line derived from PBMCs using Sendai Virus reprogramming.
BU3 NGST
Human iPSC-derived lung alveolar epithelial type 2 cells carrying an NKX2-1GFP reporter and an SFTPCtdTomato reporter.
Services
End-to-end derivation, validation, cryopreservation and cataloged distribution of iPSC lines from blood or fibroblasts with managed MTAs and shipment.
Immunostaining, gene expression panels, karyotyping and STR profiling to confirm pluripotency, identity and genomic integrity of cell lines.
Provision of iPSC-derived airway and alveolar culture models for pathogen infection studies and for in vitro antiviral or pharmacologic testing using ALI and 3D assays.
Functional assays including forskolin-induced swelling in spheroids and planar mucociliary assays to assess CFTR activity and responses to modulators across genotypes.
Differentiation to hepatocyte-like cells and use of these cultures to model viral infection dynamics, host transcriptional responses and cellular pathology.
Design and execution of CRISPR interference/perturbation experiments to interrogate gene function in iPSC-derived alveolar and other differentiated cell types.
End-to-end derivation, validation, cryopreservation and cataloged distribution of iPSC lines from blood or fibroblasts with managed MTAs and shipment.
Immunostaining, gene expression panels, karyotyping and STR profiling to confirm pluripotency, identity and genomic integrity of cell lines.
Provision of iPSC-derived airway and alveolar culture models for pathogen infection studies and for in vitro antiviral or pharmacologic testing using ALI and 3D assays.
Functional assays including forskolin-induced swelling in spheroids and planar mucociliary assays to assess CFTR activity and responses to modulators across genotypes.
Differentiation to hepatocyte-like cells and use of these cultures to model viral infection dynamics, host transcriptional responses and cellular pathology.
Design and execution of CRISPR interference/perturbation experiments to interrogate gene function in iPSC-derived alveolar and other differentiated cell types.
Expertise Areas
- iPSC derivation and biobanking
- Directed differentiation and organoid engineering
- Air-liquid interface culture for epithelial maturation
- Patient-specific disease modeling using gene-edited iPSCs
Key Technologies
- Induced pluripotent stem cell reprogramming
- Directed differentiation to alveolar, airway, hepatic and hematopoietic lineages
- 3D organoids and spheroid culture systems
- Air-liquid interface (ALI) culture
News & Updates
A bank of cells from people more than 100 years old gives scientists a resource for studying longevity.
Research collaboration to develop new treatments for pulmonary fibrosis.
Research on immune cells and tumor progression.
Announcement of Dr. Wilson's appointment as Scientific Director of the Alpha-1 Foundation.
Research on immune systems of centenarians and longevity.
Generation of AT1 cells from iPSCs that display phenotypes of primary AT1s.
A bank of cells from people more than 100 years old gives scientists a resource for studying longevity.
Research collaboration to develop new treatments for pulmonary fibrosis.
Research on immune cells and tumor progression.
Announcement of Dr. Wilson's appointment as Scientific Director of the Alpha-1 Foundation.
Research on immune systems of centenarians and longevity.
Generation of AT1 cells from iPSCs that display phenotypes of primary AT1s.